Sigma-Aldrich Empagliflozin

Empagliflozin is a C-glucoside with a carbon-carbon bond between the glucose and aglycone, resisting the breakdown in the gastrointestinal tract.[1]

Empagliflozin may be used to study its effects on diabetes mellitus in animal models.[1]

Empagliflozin (BI 10773) is an orally active, potent and highly selective sodium glucose co-transporter-2 inhibitor (hSGLT-2 IC50 = 3.1 nM; hSGLT-1/4/5/6 IC50 = 8.3/11/1.1/2.0 µM) that targets SGLT-2 with high affinity in a glucose-competitive manner (hSGLT-2 Kd = 57/194 nM in the absence/presence of 20 mM glucose). Empagliflozin improves glycaemic control in type 2 (1-3 mg/kg via daily p.o. to Zucker diabetic fatty (ZDF) rats) and type 1 (10 mg/kg b.i.d. p.o. to streptozotocin-induced diabetic (STD) rats) diabetes mellitus models.